Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK3 A572V |
| Therapy | Ilginatinib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK3 A572V | acute myeloid leukemia | predicted - resistant | Ilginatinib | Preclinical - Cell culture | Actionable | In a preclinical study, an acute myeloid leukemia cell line harboring JAK3 A572V was insensitive to treatment with Ilginatinib (NS-018) in culture (PMID: 22829185). | 22829185 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (22829185) | Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. | Full reference... |